So, again, this is the first and only approved treatment that prescribers really haven’t had to think much more beyond EDS so far to date, but we really feel good about the way that they are coming along and starting patients and we’re confident in our ability to ultimately maximize the opportunity of the product in this really underserved market.
Bruce Cozadd: Dan, do you want to jump in on the 385’s two different market opportunities? Dan, are you on mute?
Dan Swisher: I was on mute, Bruce. Thank you. Yes. So, sorry. On the sort of ET and Parkinson’s, I mean what’s similar to it is significant unmet need and, ET, there has been no new approved therapies and the therapies that are there have very little limitations, so no approved therapy in 50 years. Nothing approved for Parkinson’s tremor. We do think there’s overlapping pathophysiology between the tremor types. So — and there is some preclinical opportunity for us to as well, think the T-type calcium channel blockers should work there. In terms of the market opportunity, it’s — a couple of million have diagnosed across the Western markets. We think the actual market opportunity for essential tremor is up to 11 million, so it’s that classic.
With the right drug, you can really uncover a lot of market growth and opportunity. And then on Parkinson’s, that’s a more defined patient population and very addressable in terms of Parkinson’s treating physicians. And it’s about 1 million patients per year of which 75% have tremors, for which there is no approved therapy. So, exactly how we would configure the sales force if we’re lucky enough to get both indications is something we’ll be figuring out, but we do think from a price value as well as market coverage and interest from both HCPs and patients, it could be quite a large market.
Operator: Thank you. Our next question comes from Madhu Kumar with Goldman Sachs. Your line is open.
Omari Baruti: Good afternoon. This is Omari on for Madhu. So, our first question is how should we think about the ex-U.S. launch of Epidiolex in Europe as a like for future growth? And then, how should we think about potential opportunities for corporate development? So, you mentioned you all be open to seeking new areas. Would this be still within the core of Oncology and Neuroscience, or could you expand outside of that?
Bruce Cozadd: Okay. Let’s — I mean, in a minute, going to come to Dan on ex-U.S. Epidiolex opportunity, and then Renee on corporate development. But before that, I think there might have been a dangling part of the last question we didn’t get, which was really how to think about the two clinical trial populations and whether there’s any relationship, and how to think about potential results in essential tremor as they might apply to Parkinson’s tremors. So, Rob, maybe you could jump in on that first.
Rob Iannone: Yes. Thanks, Bruce, and I do think Dan covered it with respect to, yes, these are two distinct clinical entities, but we have strong pre-clinical rationale that the mechanism of T-type calcium channel inhibitors could help block the tremor associated with each of these conditions. So, while certainly if we see a positive readout in either of these indications, it’s going to give us increasing confidence around this molecule and working the way we think it should work. But I wouldn’t have a direct readthrough to say if it doesn’t work in one, it won’t work in the other.
